摘要
原发免疫性血小板减少症（ITP）为以血小板数目减少为特征的自身免疫性疾病.近年来,成年人ITP在发病机制、诊断、治疗等方面均获得重大进展,尤其是利妥昔单抗、血小板生成素（TPO）及血小板生成素受体激动剂（TPORA）在临床成年人ITP治疗中的广泛应用,使成年人ITP二线治疗方案的选择不再局限于脾切除术.笔者主要探讨成年人ITP患者二线治疗方案的选择,为采取一线治疗方案治疗失败的ITP患者提供个体化治疗方案.
Immune thrombocytopenia （ITP） is an autoimmune disease characterized by the decrease of platelet count.In recent years,the pathogenesis,diagnosis and treatments of adult ITP have achieved significant progress.In particular,with wide clinical applications of rituximab,thrombopoietin （TPO） and TPO receptor agonist （TPORA） in ITP,the second-line treatment options have no longer limited to splenectomy.This article mainly discusses the second-line treatment options of adult ITP after first-line treatments failure,in order to provide individualized treatments.
出处
《国际输血及血液学杂志》
CAS
2015年第1期85-89,共5页
International Journal of Blood Transfusion and Hematology
基金
国家自然科学基金,Project No.81370615
